Breaking News

Horizon Discovery Licenses ERS Genomics Technology

May 9, 2014

Will use CRISPR/Cas9 gene editing system for research applications

Horizon Discovery has entered into a non-exclusive license agreement with ERS Genomics, Ltd. to access intellectual property for the CRISPR/Cas9 gene editing system. Access to the CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D.
Horizon gains rights to use the technology for research applications including: development and sale of research tools, kits and reagents, performance of research services, creation of genetically modified disease model cell lines, development and production of reference standard material for molecular diagnostics, and for internal target identification and validation research efforts.
“Horizon Discovery’s ambition is to be the market leader in CRISPR technology, and by expanding our portfolio of intellectual property rights in this area we aim to ensure that our customers, both now and in the future, will have unencumbered access to this innovative new gene editing technology,” said Dr. Darrin Disley, chief executive officer of Horizon Discovery Group. “We believe that the ERS Genomics IP, based on the work of Dr. Emmanuelle Charpentier and her colleagues, is particularly important and so we are very pleased to be able to add it to our expanding portfolio of patent rights in this area on behalf of our customers.”

Related Compliance:

blog comments powered by Disqus
  • CROs and Today's R&D Landscape

    Kristin Brooks, Contract Pharma||May 11, 2016
    John Lewis of ACRO discusses opportunities and challenges, global markets, and the future CRO

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies